Cytosorbents Corp. Completes Asset Acquisition/Disposition
Ticker: CTSO · Form: 8-K · Filed: Aug 7, 2025 · CIK: 1175151
| Field | Detail |
|---|---|
| Company | Cytosorbents CORP (CTSO) |
| Form Type | 8-K |
| Filed Date | Aug 7, 2025 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: acquisition, disposition, assets
TL;DR
Cytosorbents just closed a deal on assets. Details TBD.
AI Summary
Cytosorbents Corp. announced on August 7, 2025, the completion of an acquisition or disposition of assets. The filing does not specify the nature of the transaction, the counterparty, or any financial details related to the event.
Why It Matters
This filing indicates a significant corporate event involving the transfer of assets, which could impact the company's operational structure and financial performance.
Risk Assessment
Risk Level: medium — The lack of specific details regarding the acquisition or disposition of assets creates uncertainty about the transaction's impact on Cytosorbents Corp.
Key Players & Entities
- Cytosorbents Corp (company) — Registrant
- August 7, 2025 (date) — Date of Report
- MedaSorb Technologies CORP (company) — Former Company Name
- GILDER ENTERPRISES INC (company) — Former Company Name
FAQ
What specific assets were acquired or disposed of by Cytosorbents Corp?
The filing does not specify the nature of the assets involved in the transaction.
Who was the counterparty in this acquisition or disposition of assets?
The filing does not disclose the name of the other party involved in the transaction.
What was the financial value of the completed asset transaction?
The filing does not provide any financial figures related to the acquisition or disposition of assets.
When did the event triggering this 8-K filing occur?
The earliest event reported occurred on August 7, 2025.
What is the primary business of Cytosorbents Corp?
Cytosorbents Corp. is in the business of Surgical & Medical Instruments & Apparatus, SIC code 3841.
Filing Stats: 499 words · 2 min read · ~2 pages · Grade level 11.5 · Accepted 2025-08-07 16:22:45
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 par value NASDAQ Check the appropri
Filing Documents
- a8k.htm (8-K) — 24KB
- exhbit99-1.htm (EX-99) — 430KB
- image0.jpg (GRAPHIC) — 96KB
- 0000929638-25-002927.txt ( ) — 746KB
- ctso-20250807.xsd (EX-101.SCH) — 4KB
- ctso-20250807_lab.xml (EX-101.LAB) — 21KB
- ctso-20250807_pre.xml (EX-101.PRE) — 16KB
- a8k_htm.xml (XML) — 4KB
02
Item 2.02 Results of Operation and Financial Condition On August 7, 2025, CytoSorbents Corporation issued a press release announcing its financial results for the quarter ended June 30, 2025. A copy of the press release is furnished herewith as Exhibit 99.1.*
01
Item 9.01 Exhibits (d) Exhibits Exhibit No. Description 99.1 Press Release of the Company, dated August 7, 2025 104 Cover Page Interactive Data File (embedded with the Inline XBRL document) * The information in Item 2.02 of this Form 8-K shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: August 7, 2025 CYTOSORBENTS CORPORATION By: /s/ Dr. Phillip P. Chan Name: Dr. Phillip P. Chan Title: Chief Executive Officer